EUVIMEDEUVIMED entdecken
Open Access

Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy

Jianfei Xu iD, Xiaoran Zhao, Xingxing Liang, Dongyang Guo, Jing Wang, Qian Wang iD, Xinjing Tang iD

Science Advances · 20.09.2024 · 10 (38)

DOI: 10.1126/sciadv.adp0334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 20.09.2024. Verfasst von Jianfei Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center and School of Pharmaceutical Sciences, Peking University, Xueyuan Rd, B…. Hauptthemen laut MEDLINE: MicroRNAs, RNA-Binding Proteins, Breast Neoplasms, Proteolysis. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lin28, a highly conserved carcinogenic protein, plays an important role in the generation of cancer stem cells, contributing to the unfavorable prognosis of cancer patients. This RNA binding protein specifically binds to pri/pre-microRNA (miRNA) lethal-7 (let-7), impeding its miRNA maturation. The reduced expression of tumor suppressor miRNA let-7 fosters development and progression-related traits such as proliferation, invasion, metastasis, and drug resistance. We report a series of miRNA-based Lin28A-miRNA proteolysis-targeting chimeras (Lin28A-miRNA-PROTACs) designed to efficiently degrade Lin28A through a ubiquitin-proteasome–dependent mechanism, resulting in up-regulation of mature let-7 family. The augmented levels of matured let-7 miRNAs further exert inhibitory effects on cancer cell proliferation and migration, and increase its sensitivity to chemotherapy. In a mouse ectopic tumor model, Lin28A-miRNA-PROTAC demonstrates a substantial efficacy in inhibiting tumor growth. When combined with tamoxifen, the tumors exhibit gradual regression. This study displays an effective miRNA-based PROTACs to degrade Lin28A and inhibit tumor growth, providing a promising therapeutic avenue for cancer treatment with miRNA-based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsRNA-Binding ProteinsBreast NeoplasmsProteolysisCell ProliferationHumansAnimalsFemaleMiceCell Line, TumorGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysCell MovementProteasome Endopeptidase ComplexProteolysis Targeting Chimera

Substanzen

MicroRNAsRNA-Binding ProteinsLin28A protein, humanmirnlet7 microRNA, humanProteasome Endopeptidase ComplexProteolysis Targeting Chimera

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center and School of Pharmaceutical Sciences, Peking University, Xueyuan Rd, Beijing 100191, China.

ORCID-Profile: Jianfei Xu, Qian Wang, Xinjing Tang

Zitieren

APA

Xu, J., Zhao, X., Liang, X., Guo, D., Wang, J., Wang, Q., & Tang, X. (2024). Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy. Science Advances, 10(38). https://doi.org/10.1126/sciadv.adp0334

Vancouver

Xu J, Zhao X, Liang X, Guo D, Wang J, Wang Q, et al. Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy. Science Advances. 2024;10(38). doi:10.1126/sciadv.adp0334

BibTeX
@article{Xu2024,
  author = {Xu, Jianfei and Zhao, Xiaoran and Liang, Xingxing and Guo, Dongyang and Wang, Jing and Wang, Qian and Tang, Xinjing},
  title = {Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {38},
  doi = {10.1126/sciadv.adp0334}
}
Kostenlos starten →